Effect of ibrutinib given either alone or in combination with rituximab or bendamustine in patients with Chronic Lymphocytic Leukemia and having complex metaphase karyotype and del(17p)

Trial Profile

Effect of ibrutinib given either alone or in combination with rituximab or bendamustine in patients with Chronic Lymphocytic Leukemia and having complex metaphase karyotype and del(17p)

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 May 2015

At a glance

  • Drugs Ibrutinib (Primary) ; Bendamustine; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top